BioSpace News Archive

InStatin & InVixa Are Developing Novel Treatments for COVID-19, Asthma, and Chronic Obstructive Pulmonary Disease (COPD)

In recent months, several media outlets have investigated an Oregon law that decriminalized possession of small amounts of controlled substances, including heroin, cocaine and methamphetamine, for some persons.

The Pulmonary Fibrosis Foundation (PFF) will present its biennial PFF Summit 2023 from Nov. 9-11 in Orlando, Fla. The three-day international conference, focused on pulmonary fibrosis (PF) and interstitial lung disease (ILD) research and education, will be held at the JW Marriott Orlando Grande Lakes.

Iovance Biotherapeutics, Inc. announced poster presentations reporting clinical data and trial design for tumor infiltrating lymphocyte therapies at the Society for Immunotherapy of Cancer’s 38th Annual Meeting in San Diego, CA, November 1-5, 2023.

Gritstone bio, Inc. announced that it was awarded a contract by the Biomedical Advanced Research and Development Authority to conduct a Phase 2b comparative study evaluating Gritstone’s self-amplifying mRNA vaccine candidate containing Spike plus other viral targets to protect against COVID-19.

Supernus Pharmaceuticals, Inc. announced that it will host and webcast a Research & Development Day on Wednesday, October 18, 2023.

Cellectis announced that pre-clinical data on MUC1-CAR T-cells to overcome key challenges of targeting solid tumors, will be presented at the Society for Immunotherapy of Cancer’s 38th Annual Meeting, that will take place on November 1-5, 2023 at San Diego Convention Center in San Diego.

Aytu BioPharma, Inc.announced financial and operational results for the fourth quarter and fiscal year ended June 30, 2023.

The Owens & Minor Foundation shared its achievements over the past year in delivering on its efforts to help build healthier communities.

MediciNova, Inc. announced the results of the nonclinical studies conducted under its contract with the BARDA, part of the Administration for Strategic Preparedness and Response in the U.S. Department of Health and Human Services, to repurpose MN-166 as a potential medical countermeasure against chlorine gas-induced lung damage such as acute respiratory distress syndrome and acute lung injury.